WVE in the 13F filings
Wave Life Sciences LTD · CUSIP Y95308105
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 1 listed it in both
- Shares listed
- 38,238,836
- combined, among listed positions
- Reported value
- $650m
- combined, at the quarter end
Among the 92 comparable managers: 17 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +14,764,366.
Managers listing WVE in Q4 2025
22 of 22 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 15,135,983 shares now+10,005,609
- T. Rowe Price Associates Incexisting position · 7,407,372 shares now+3,362,880
- Maverick Capital Ltdexisting position · 9,280,237 shares now+888,381
- Citadel Advisors LLCnew position · 789,964 shares now+789,964
- Voloridge Investment Management LLCnew position · 722,237 shares now+722,237
Reductions
- Jane Street Group LLCexisting position · 110,924 shares now-508,717
- Walleye Capital LLCexisting position · 378,823 shares now-351,816
- Man Group PLCexisting position · 31,418 shares now-101,353
- Wellington Management Group LLPexisting position · 365,235 shares now-64,384
New positions and exits
New (7)
Exited (6)
- Artisan Partners LPwas $9.0m
- Point72 Asset Management LPwas $4.9m
- Two Sigma Advisers LPwas $1.8m
- ExodusPoint Capital Management LPwas $689k
- Balyasny Asset Management LLCwas $135k
- Marshall Wace LLPwas $102k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2017 | 1 | $14m | n.a. | n.a. |
| Q4 2017 | 1 | $3.0m | n.a. | n.a. |
| Q1 2018 | 2 | $3.4m | n.a. | n.a. |
| Q2 2018 | 3 | $16m | n.a. | n.a. |
| Q3 2018 | 4 | $98m | n.a. | n.a. |
| Q4 2018 | 3 | $90m | n.a. | n.a. |
| Q1 2019 | 5 | $141m | n.a. | n.a. |
| Q2 2019 | 3 | $90m | n.a. | n.a. |
| Q3 2019 | 2 | $85m | n.a. | n.a. |
| Q4 2019 | 1 | $447k | n.a. | n.a. |
| Q1 2020 | 1 | $1.1m | n.a. | n.a. |
| Q2 2020 | 1 | $623k | n.a. | n.a. |
| Q3 2020 | 3 | $2.3m | n.a. | n.a. |
| Q4 2020 | 2 | $2.3m | n.a. | n.a. |
| Q1 2021 | 1 | $17m | n.a. | n.a. |
| Q2 2021 | 1 | $21m | n.a. | n.a. |
| Q3 2021 | 1 | $16m | n.a. | n.a. |
| Q4 2021 | 1 | $18m | n.a. | n.a. |
| Q1 2022 | 1 | $11m | n.a. | n.a. |
| Q2 2022 | 1 | $25m | n.a. | n.a. |
| Q3 2022 | 3 | $30m | n.a. | n.a. |
| Q4 2022 | 3 | $59m | n.a. | n.a. |
| Q1 2023 | 2 | $31m | n.a. | n.a. |
| Q2 2023 | 1 | $24m | n.a. | n.a. |
| Q3 2023 | 2 | $45m | n.a. | n.a. |
| Q4 2023 | 2 | $50m | 2 | 0 |
| Q1 2024 | 2 | $53m | 0 | 2 |
| Q2 2024 | 2 | $39m | 1 | 1 |
| Q3 2024 | 4 | $103m | 3 | 1 |
| Q4 2024 | 4 | $132m | 0 | 3 |
| Q1 2025 | 2 | $86m | 2 | 0 |
| Q2 2025 | 2 | $68m | 0 | 1 |
| Q3 2025 | 2 | $70m | 1 | 1 |
| Q4 2025 | 1 | $158m | 17 | 10 |
| Q1 2026 | 1 | $74m | 20 | 5 |
| Q2 2026 | 1 | $60m | 16 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
WVE and LLY →WVE and JNJ →WVE and VRTX →Choose a stock to compare with WVE →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own WVE, latest filings →Back to the 13F Explorer →